{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:17:06Z","timestamp":1784931426906,"version":"3.55.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002865","name":"Chongqing Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["CSTB2025NSCQ-GPX0396"],"award-info":[{"award-number":["CSTB2025NSCQ-GPX0396"]}],"id":[{"id":"10.13039\/501100002865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007957","name":"Chongqing Municipal Education Commission","doi-asserted-by":"publisher","award":["KJZD-K202300408"],"award-info":[{"award-number":["KJZD-K202300408"]}],"id":[{"id":"10.13039\/501100007957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203213"],"award-info":[{"award-number":["82203213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203844"],"award-info":[{"award-number":["82203844"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81911530169"],"award-info":[{"award-number":["81911530169"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515140151"],"award-info":[{"award-number":["2024A1515140151"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017501","name":"Science-Health Joint Medical Scientific Research Project of Chongqing","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013160","name":"Venture and Innovation Support Program for Chongqing Overseas Returnees","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013160","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Innovation"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.xinn.2026.101344","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:31:46Z","timestamp":1773246706000},"page":"101344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unmasking hidden high risk in RUNX1::RUNX1T1 pediatric AML: Development of a novel prognostic model"],"prefix":"10.1016","volume":"7","author":[{"given":"Yang","family":"Xun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yance","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8379-9684","authenticated-orcid":false,"given":"Yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan K.","family":"Bohlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xinn.2026.101344_bib1","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.htct.2018.09.007","article-title":"Cytogenetic abnormalities, who classification, and evolution of children and adolescents with acute myeloid leukemia","volume":"41","author":"Nunes","year":"2019","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"10.1016\/j.xinn.2026.101344_bib2","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1200\/JCO.2009.25.6321","article-title":"Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial aml-bfm 98","volume":"28","author":"von Neuhoff","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xinn.2026.101344_bib3","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1182\/blood.2020006152","article-title":"Born to runx1","volume":"135","author":"Sung","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.xinn.2026.101344_bib4","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1182\/blood-2009-09-241075","article-title":"Prevalence and prognostic significance of kit mutations in pediatric patients with core binding factor aml enrolled on serial pediatric cooperative trials for de novo aml","volume":"115","author":"Pollard","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.xinn.2026.101344_bib5","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of aml in adults: 2017 eln recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.xinn.2026.101344_bib6","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of aml in adults: 2022 recommendations from an international expert panel on behalf of the eln","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.xinn.2026.101344_bib7","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1200\/JCO.20.03048","article-title":"Gemtuzumab ozogamicin improves event-free survival and reduces relapse in pediatric kmt2a-rearranged aml: Results from the phase iii children's oncology group trial aaml0531","volume":"39","author":"Pollard","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xinn.2026.101344_bib8","first-page":"407","article-title":"Revised risk stratification criteria for children with newly diagnosed acute myeloid leukemia: A report from the children's oncology group","volume":"130","author":"Cooper","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.xinn.2026.101344_bib9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/JCO.18.00313","article-title":"Occurrence of treatment-related cardiotoxicity and its impact on outcomes among children treated in the aaml0531 clinical trial: A report from the children's oncology group","volume":"37","author":"Getz","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xinn.2026.101344_bib10","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.5045\/br.2020.S002","article-title":"Treatments for children and adolescents with aml","volume":"55","author":"Kim","year":"2020","journal-title":"Blood Res."},{"key":"10.1016\/j.xinn.2026.101344_bib11","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1200\/JCO.22.01114","article-title":"Long noncoding rna expression independently predicts outcome in pediatric acute myeloid leukemia","volume":"41","author":"Farrar","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xinn.2026.101344_bib12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41408-024-01144-1","article-title":"Multiomic analysis identifies a high-risk subgroup that predicts poor prognosis in t(8;21) acute myeloid leukemia","volume":"14","author":"Liu","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.xinn.2026.101344_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/children11050605","article-title":"Prognostic factors of pediatric acute myeloid leukemia patients with t(8;21) (q22;q22): A single-center retrospective study","volume":"11","author":"Yang","year":"2024","journal-title":"Children"},{"key":"10.1016\/j.xinn.2026.101344_bib14","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/blood.2019001425","article-title":"Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): Results from the aml study group","volume":"134","author":"R\u00fccker","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.xinn.2026.101344_bib15","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xinn.2026.101344_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104511","article-title":"Targeting glucose metabolism to suppress cancer progression: Prospective of anti-glycolytic cancer therapy","volume":"150","author":"Abdel-Wahab","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.xinn.2026.101344_bib17","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: Results from the randomized phase iii children\u2019s oncology group trial aaml0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xinn.2026.101344_bib18","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1200\/JCO.21.01612","article-title":"Sorafenib in combination with standard chemotherapy for children with high allelic ratio flt3\/itd+ acute myeloid leukemia: A report from the children's oncology group protocol aaml1031","volume":"40","author":"Pollard","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xinn.2026.101344_bib19","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2017-03-772384","article-title":"Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: A children's oncology group report","volume":"129","author":"Vujkovic","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.xinn.2026.101344_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbab260","article-title":"Oncopredict: An r package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data","volume":"22","author":"Maeser","year":"2021","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.xinn.2026.101344_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/1471-2105-7-123","article-title":"Detecting outliers when fitting data with nonlinear regression - a new method based on robust nonlinear regression and the false discovery rate","volume":"7","author":"Motulsky","year":"2006","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.xinn.2026.101344_bib22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/biostatistics\/kxr047","article-title":"A measure of explained risk in the proportional hazards model","volume":"13","author":"Heller","year":"2012","journal-title":"Biostatistics"},{"key":"10.1016\/j.xinn.2026.101344_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29313","article-title":"Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the children's oncology group","volume":"69","author":"Getz","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.xinn.2026.101344_bib24","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3760\/cma.j.issn.0366-6999.20132107","article-title":"The percentage of peripheral blood blasts on day 7 of induction chemotherapy predicts response to therapy and survival in patients with acute myeloid leukemia","volume":"127","author":"Gao","year":"2014","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.xinn.2026.101344_bib25","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in aml: A consensus document from the european leukemianet mrd working party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.xinn.2026.101344_bib26","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/s41375-024-02217-7","article-title":"Targeting the innate immune system in pediatric and adult aml","volume":"38","author":"Perzolli","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.xinn.2026.101344_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2024.1436244","article-title":"Regional differences, dynamic evolution, and influencing factors of high-quality medical resources in china's ethnic minority areas","volume":"12","author":"Liang","year":"2024","journal-title":"Front. Public Health"},{"key":"10.1016\/j.xinn.2026.101344_bib28","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/bloodadvances.2019000709","article-title":"Prospective evaluation of prognostic impact of kit mutations on acute myeloid leukemia with runx1-runx1t1 and cbfb-myh11","volume":"4","author":"Ishikawa","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.xinn.2026.101344_bib29","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1158\/1078-0432.CCR-18-1897","article-title":"Functional properties of kit mutations are associated with differential clinical outcomes and response to targeted therapeutics in cbf acute myeloid leukemia","volume":"25","author":"Tarlock","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xinn.2026.101344_bib30","first-page":"251","article-title":"Adverse prognostic impact of kit exon 17 mutations despite negative flow cytometric measurable residual disease in pediatric acute myeloid leukemia with runx1::Runx1t1","volume":"110","author":"Kato","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.xinn.2026.101344_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2023.100503","article-title":"Synergistic targeting of DNA-pk and kit signaling pathways in kit mutant acute myeloid leukemia","volume":"22","author":"Murray","year":"2023","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.xinn.2026.101344_bib32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2018.04.020","article-title":"The role of small molecule kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders","volume":"133","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.xinn.2026.101344_bib33","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s40262-021-01054-6","article-title":"Population pharmacokinetics and safety of dasatinib in chinese children with core-binding factor acute myeloid leukemia","volume":"61","author":"Yang","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.xinn.2026.101344_bib34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/bjh.17125","article-title":"Use of an anti-cd200-blocking antibody improves immune responses to aml in vitro and in vivo","volume":"193","author":"Rastogi","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.xinn.2026.101344_bib35","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-014-0053-9","article-title":"Chk1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor mk-1775 in acute myeloid leukemia cells","volume":"7","author":"Qi","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xinn.2026.101344_bib36","first-page":"167","article-title":"Pi3k abrogation using pan-pi3k inhibitor bkm120 gives rise to a significant anticancer effect on aml-derived kg-1 cells by inducing apoptosis and g2\/m arrest","volume":"37","author":"Sadeghi","year":"2020","journal-title":"Turk. J. Haematol."},{"key":"10.1016\/j.xinn.2026.101344_bib37","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/leu.2014.4","article-title":"High number of additional genetic lesions in acute myeloid leukemia with t(8;21)\/runx1-runx1t1: Frequency and impact on clinical outcome","volume":"28","author":"Krauth","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.xinn.2026.101344_bib38","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1182\/blood-2014-04-571018","article-title":"Frequent asxl2 mutations in acute myeloid leukemia patients with t(8;21)\/runx1-runx1t1 chromosomal translocations","volume":"124","author":"Micol","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.xinn.2026.101344_bib39","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/s41375-019-0697-0","article-title":"The clinical mutatome of core binding factor leukemia","volume":"34","author":"Opatz","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.xinn.2026.101344_bib40","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1182\/blood-2012-03-419622","article-title":"A novel hierarchical prognostic model of aml solely based on molecular mutations","volume":"120","author":"Grossmann","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.xinn.2026.101344_bib41","article-title":"A simplified and robust risk stratification model for stem cell transplantation in pediatric acute myeloid leukemia","volume":"5","author":"Yang","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xinn.2026.101344_bib42","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1200\/JCO.23.00943","article-title":"Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin with gemtuzumab ozogamicin improves event-free survival in younger patients with newly diagnosed aml and overall survival in patients with npm1 and flt3 mutations","volume":"42","author":"Russell","year":"2024","journal-title":"J. Clin. Oncol."}],"container-title":["The Innovation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666675826000913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666675826000913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T20:21:02Z","timestamp":1783714862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666675826000913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2666675826000913"],"URL":"https:\/\/doi.org\/10.1016\/j.xinn.2026.101344","relation":{},"ISSN":["2666-6758"],"issn-type":[{"value":"2666-6758","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unmasking hidden high risk in RUNX1::RUNX1T1 pediatric AML: Development of a novel prognostic model","name":"articletitle","label":"Article Title"},{"value":"The Innovation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xinn.2026.101344","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of Youth Innovation Co., Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101344"}}